ABEI-Based Automated Immunoassays for PIVKA-II Testing

Area of Science:

• Clinical Chemistry
• Immunoassay Technology
• Biomarker Analysis

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• PIVKA-II (Protein Induced by Vitamin K Absence or Antagonism II) is a key biomarker for HCC detection.
• Accurate quantification of PIVKA-II is crucial for effective HCC management.

Purpose of the Study:

• To evaluate the analytical performance of the Maglumi® X6 automated immunoassay for PIVKA-II.
• To compare the Maglumi® X6 assay with the established Lumipulse® assay for PIVKA-II quantification.
• To establish reference ranges for PIVKA-II in a healthy population.

Main Methods:

• Analytical performance assessed using CLSI EP15-A3 guidelines with internal quality controls.
• Imprecision and accuracy evaluated through multiple daily measurements over five days.
• Method comparison conducted on 63 patient serum samples against the Lumipulse® assay.

Main Results:

• Maglumi® X6 demonstrated low within-run and between-run coefficients of variation (CVs).
• Accuracy assessments showed minimal bias at both low and high concentrations.
• Strong correlation (r=0.95) observed when comparing Maglumi® X6 with Lumipulse®, with a mean bias of 49.9 mAU/mL.
• The 95th percentile for PIVKA-II in healthy individuals was determined to be 45 mAU/mL.

Conclusions:

• The Maglumi® X6 ABEI-based immunoassay exhibits robust analytical performance for PIVKA-II.
• The assay shows promise as a reliable tool for PIVKA-II quantification in clinical settings.
• Further clinical validation in larger patient cohorts is recommended to confirm its utility in HCC diagnosis and management.